nivolumab
bms
['nadim ii', 'nadim', 'nivolumab', 'lcsm,(-blcsm)', 'nivo']
#asco22 primary endpoint of nadim ii was pathologic cr (pcr) in itt. more never smokers and more n2 involvement in experimental arm (may work a little against the nivolumab arm, if anything). #lcsm 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him